Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-428010

Options or other derivatives

  • Chief Financial Officer acquired 25,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Silver Andrew Jacob · Chief Financial Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-10-19 Grant or award : show line 1 in the form Restricted Stock Units +25,000 25,000 D
Loading xslF345X06/ownership.xml…